DRUG · Unmapped registry intervention
TAVT-45
Find medicine records ·
Find other trials using this name
Clinical trial
TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer
NCT04887506
Drugs and interventions used in this trial
3 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Mapped RxNorm record
Zytiga
Normalized identity: ZytigaView linked drug · Find medicine records ·
Find other trials using this name
DRUG · Mapped RxNorm record
Prednisone
Normalized identity: prednisoneView linked drug · Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedTAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE3
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Interventions
Sponsors & collaborators
Tavanta Therapeuticslead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT04887506 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.